The prevalence of severe refractory asthma

Published:October 14, 2014DOI:


      Severe asthma is characterized by difficulty to achieve disease control despite high-intensity treatment. However, prevalence figures of severe asthma are lacking, whereas longstanding estimates vary between 5% and 10% of all asthmatic patients. Knowing the exact prevalence of severe refractory asthma as opposed to difficult-to-control asthma is important for clinical decision making, drug development, and reimbursement policies by health authorities.


      We sought to estimate the prevalence of severe refractory asthma as defined by the Innovative Medicine Initiative consensus.


      Adult patients with a prescription for high-intensity treatment (high-dose inhaled corticosteroids and long-acting β2-agonists or medium- to high-dose inhaled corticosteroids combined with oral corticosteroids and long-acting β2-agonists) were extracted from 65 Dutch pharmacy databases, representing 3% of the population (500,500 inhabitants). Questionnaires were sent to 5,002 patients, of which 2,312 were analyzed. The diagnosis of asthma and degree of asthma control were derived from questionnaires to identify patients with difficult-to-control asthma. Inhalation technique was assessed in a random sample of 60 adherent patients (prescription filling, ≥80%). Patients with difficult-to-control asthma, adherence to treatment, and a correct inhalation technique were qualified as having severe refractory asthma. Results were mirrored to the Dutch population.


      Of asthmatic adults, 3.6% (95% CI, 3.0% to 4.1%) qualified for a diagnosis of severe refractory asthma, representing 10.4 patients per 10,000 inhabitants.


      The prevalence of severe refractory asthma might be lower than estimated by expert opinion. This implies that currently recognized severe asthma subphenotypes could meet the criteria of rare diseases.

      Key words

      Abbreviations used:

      ACQ (Asthma Control Questionnaire), COPD (Chronic obstructive pulmonary disease), ICS (Inhaled corticosteroid), IMI (Innovative Medicine Initiative), LABA (Long-acting β2-agonist), OCS (Oral corticosteroid)
      To read this article in full you will need to make a payment


      Subscribe to Journal of Allergy and Clinical Immunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Martinez F.D.
        • Vercelli D.
        Lancet. 2013; 382: 1360-1372
        • Barnes P.J.
        • Woolcock A.J.
        Difficult asthma.
        Eur Respir J. 1998; 12: 1209-1218
        • Busse W.W.
        • Banks-Schlegel S.
        • Wenzel S.E.
        Pathophysiology of severe asthma.
        J Allergy Clin Immunol. 2000; 106: 1033-1042
        • O'Byrne P.M.
        • Naji N.
        • Gauvreau G.M.
        Severe asthma: future treatments.
        Clin Exp Allergy. 2012; 42: 706-711
        • Bel E.H.
        • Sousa A.
        • Fleming L.
        • Bush A.
        • Chung K.F.
        • Versnel J.
        • et al.
        Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).
        Thorax. 2011; 66: 910-917
        • Garcia-Cardenas V.
        • Sabater-Hernandez D.
        • Kenny P.
        • Martinez-Martinez F.
        • Faus M.J.
        • Benrimoj S.I.
        Effect of a pharmacist intervention on asthma control. A cluster randomised trial.
        Respir Med. 2013; 107: 1346-1355
        • Chung K.F.
        • Wenzel S.E.
        • Brozek J.L.
        • Bush A.
        • Castro M.
        • Sterk P.J.
        • et al.
        International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.
        Eur Respir J. 2014; 43: 343-373
        • Buurma H.
        • Bouvy M.L.
        • De Smet P.A.
        • Floor-Schreudering A.
        • Leufkens H.G.
        • Egberts A.C.
        Prevalence and determinants of pharmacy shopping behaviour.
        J Clin Pharm Ther. 2008; 33: 17-23
        • Juniper E.F.
        • Bousquet J.
        • Abetz L.
        • Bateman E.D.
        Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire.
        Respir Med. 2006; 100: 616-621
        • McNicholl D.M.
        • Stevenson M.
        • McGarvey L.P.
        • Heaney L.G.
        The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma.
        Am J Respir Crit Care Med. 2012; 186: 1102-1108
        • Rootmensen G.N.
        • van Keimpema A.R.
        • Jansen H.M.
        • de Haan R.J.
        Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method.
        J Aerosol Med Pulm Drug Deliv. 2010; 23: 323-328
      1. RIVM, Nationaal Kompas Volksgezondheid. Astma, hoe vaak komt het voor en hoeveel mensen sterven eraan? 2004. Available at: Accessed April 2013.

      2. Centraal Bureau voor de Statistiek. Available at:,3-51&D2=61&HDR=G1&STB=T&VW=T. Accessed April 2013.

        • Wener R.R.
        • Bel E.H.
        Severe refractory asthma: an update.
        Eur Respir Rev. 2013; 22: 227-235
        • Holgate S.T.
        • Polosa R.
        The mechanisms, diagnosis, and management of severe asthma in adults.
        Lancet. 2006; 368: 780-793
        • Murphy A.C.
        • Proeschal A.
        • Brightling C.E.
        • Wardlaw A.J.
        • Pavord I.
        • Bradding P.
        • et al.
        The relationship between clinical outcomes and medication adherence in difficult-to-control asthma.
        Thorax. 2012; 67: 751-753
        • Gamble J.
        • Stevenson M.
        • McClean E.
        • Heaney L.G.
        The prevalence of nonadherence in difficult asthma.
        Am J Respir Crit Care Med. 2009; 180: 817-822
        • Williams L.K.
        • Pladevall M.
        • Xi H.
        • Peterson E.L.
        • Joseph C.
        • Lafata J.E.
        • et al.
        Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma.
        J Allergy Clin Immunol. 2004; 114: 1288-1293
        • Giraud V.
        • Roche N.
        Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability.
        Eur Respir J. 2002; 19: 246-251
        • Molimard M.
        • Raherison C.
        • Lignot S.
        • Depont F.
        • Abouelfath A.
        • Moore N.
        Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care.
        J Aerosol Med. 2003; 16: 249-254
        • Basheti I.A.
        • Reddel H.K.
        • Armour C.L.
        • Bosnic-Anticevich S.Z.
        Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists.
        J Allergy Clin Immunol. 2007; 119: 1537-1538
        • Langley S.J.
        • Goldthorpe S.
        • Craven M.
        • Morris J.
        • Woodcock A.
        • Custovic A.
        Exposure and sensitization to indoor allergens: association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma.
        J Allergy Clin Immunol. 2003; 112: 362-368
        • Boulet L.P.
        Influence of comorbid conditions on asthma.
        Eur Respir J. 2009; 33: 897-906
        • Bateman E.D.
        • Bousquet J.
        • Busse W.W.
        • Clark T.J.
        • Gul N.
        • Gibbs M.
        • et al.
        Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study.
        Allergy. 2008; 63: 932-938
        • Mehuys E.
        • Van Bortel L.
        • De Bolle L.
        • Van Tongelen I.
        • Annemans L.
        • Remon J.P.
        • et al.
        Effectiveness of pharmacist intervention for asthma control improvement.
        Eur Respir J. 2008; 31: 790-799
        • Moore W.C.
        • Meyers D.A.
        • Wenzel S.E.
        • Teague W.G.
        • Li H.
        • Li X.
        • et al.
        Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.
        Am J Respir Crit Care Med. 2010; 181: 315-323
        • Wenzel S.E.
        • Busse W.W.
        Severe asthma: lessons from the Severe Asthma Research Program.
        J Allergy Clin Immunol. 2007; 119: 14-21